Risk reduction of medication-related osteonecrosis of the jaw

N. Yarom*, S. Fedele

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Management of Medication-Related Osteonecrosis of the Jaw is challenging and outcomes of treatment are unpredictable. There is wide consensus that risk of ONJ can be, at least in part, reduced through control of a number of factors associated with increased likelihood of ONJ development. Robust evidence however remains limited. The aim of this chapter is to provide a comprehensive summary of available evidence upon riskreduction measures for patients at risk of ONJ.

Original languageEnglish
Title of host publicationMedication-Related Osteonecrosis of the Jaws
Subtitle of host publicationBisphosphonates, Denosumab, and New Agents
PublisherSpringer Berlin Heidelberg
Pages149-153
Number of pages5
ISBN (Electronic)9783662437339
ISBN (Print)9783662437322
DOIs
StatePublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'Risk reduction of medication-related osteonecrosis of the jaw'. Together they form a unique fingerprint.

Cite this